Tritonpoint Wealth LLC Sells 1,938 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Tritonpoint Wealth LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 70.0% during the fourth quarter, HoldingsChannel reports. The firm owned 829 shares of the biopharmaceutical company’s stock after selling 1,938 shares during the quarter. Tritonpoint Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $640,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of REGN. Salomon & Ludwin LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Regeneron Pharmaceuticals in the second quarter valued at about $31,000. Board of the Pension Protection Fund bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $31,000. Caitlin John LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth about $34,000. Finally, FNY Investment Advisers LLC bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $38,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: EYLEA HD (aflibercept) received FDA approval with extended dosing intervals up to five months for wAMD and DME — this can raise lifetime patient value, reduce treatment burden, and boost Regeneron’s retina revenue and competitive positioning. EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
• Positive Sentiment: Regeneron struck a strategic collaboration with TriNetX to access ~300 million de‑identified EHR records, giving it broader phenotypic linkage to its genomic/proteomic datasets — this should accelerate target discovery, improve clinical-trial design, and strengthen AI-driven drug development over time. Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
• Positive Sentiment: Analyst commentary and Zacks/Yahoo pieces highlight Regeneron’s strong earnings‑surprise history and factors that point to another potential beat — supporting short‑term investor optimism ahead of upcoming results. Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Regeneron told investors it expects to be excluded from the U.S. list facing proposed pharma tariffs — that reduces near‑term policy risk and potential margin pressure relative to peers. Regeneron says it expects to avoid new US pharma tariffs
• Neutral Sentiment: Piper Sandler has initiated coverage of Regeneron (details of the call/rating were not in the summary) — coverage can increase attention/liquidity but the impact depends on the firm’s stated rating and model. Piper Sandler Begins Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN)

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 5,274 shares of company stock valued at $4,142,738. Company insiders own 7.02% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. raised their price target on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Evercore increased their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research note on Thursday, January 22nd. Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a research report on Monday, March 2nd. Truist Financial decreased their target price on shares of Regeneron Pharmaceuticals from $818.00 to $801.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Finally, Piper Sandler began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 31st. They issued an “overweight” rating and a $875.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $804.70.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $761.85 on Friday. The company has a 50 day simple moving average of $766.62 and a 200 day simple moving average of $713.93. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The firm has a market cap of $80.54 billion, a PE ratio of 18.33, a price-to-earnings-growth ratio of 2.02 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the firm posted $12.07 EPS. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were paid a $0.94 dividend. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.05%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.